How Much Does Cancer Immunotherapy Cost Beyond CAR-T — And What Will Insurance Actually Cover?

CAR-T therapy's eye-catching list price — often exceeding a million dollars per treatment — has been widely reported, including previously on this site. But the far more common form of cancer immunotherapy that most patients actually receive is checkpoint inhibitor infusions like pembrolizumab (Keytruda) or nivolumab (Opdivo), given every few weeks, often for a year or more. This article covers what those drugs actually cost, how Medicare and private insurance typically handle them, and where real financial help exists for patients facing this less-discussed but still substantial cost burden.

The List Price: A Recurring, Not One-Time, Expense

Unlike CAR-T, which is a single infusion, checkpoint inhibitors are typically given every three to six weeks, often for up to two years or until the cancer progresses. Pembrolizumab currently carries a list price of roughly $22,675 every six weeks — which works out to approximately $191,000 per year at list price. Nivolumab and other checkpoint inhibitors fall in a broadly similar range. These are manufacturer list prices, not what any individual patient or insurer typically pays after negotiated discounts and rebates, but they set the baseline that insurance coverage and cost-sharing get calculated from.

How Medicare Covers Immunotherapy

For patients on Original Medicare, checkpoint inhibitor infusions given in a clinical setting are generally covered under Medicare Part B, since they're physician-administered rather than self-administered pills. After meeting the annual Part B deductible, patients are typically responsible for 20% coinsurance on the Medicare-approved amount — a percentage that sounds modest until you apply it to a drug costing close to $200,000 a year. On a full year of pembrolizumab at list price, a straightforward 20% coinsurance would come to roughly $38,000 out of pocket, before any supplemental coverage. Medicare Advantage and Medigap supplemental plans can substantially reduce that exposure, but coverage specifics vary significantly by plan, which is exactly why this figure is worth understanding before treatment starts rather than after the first bill arrives.

Private Insurance and the Prior Authorization Hurdle

Most private insurance plans do cover FDA-approved checkpoint inhibitors for their approved indications, but coverage is routinely conditioned on prior authorization — a process requiring the oncologist to document that the specific cancer type, stage, and biomarker status match an FDA-approved or National Comprehensive Cancer Network-recommended use before the insurer will pay. This isn't a formality: prior authorization denials and delays are a genuine, well-documented source of treatment delay for cancer patients, and appealing a denial can take weeks precisely when patients don't have weeks to spare. Patients and caregivers should ask their oncology team's financial counselor to flag prior authorization status before the first infusion is scheduled, not after.

The Real Gap: What Patients Actually Pay

The honest range is wide and depends heavily on plan design: patients with robust employer coverage or Medicare plus strong supplemental coverage may pay relatively little out of pocket for FDA-approved use; patients with high-deductible plans, Medicare without supplemental coverage, or coverage gaps can face tens of thousands of dollars in a single year. Financial toxicity — the term researchers and oncologists use for the financial strain of cancer treatment itself — is now recognized as a real driver of worse outcomes, including patients skipping or delaying doses because of cost, which is precisely why this deserves the same direct treatment as the clinical facts of immunotherapy.

Where Real Financial Help Exists

This is genuinely useful, actionable information for patients facing these numbers today. Manufacturer patient assistance programs — such as the Merck Access Program for Keytruda — can substantially reduce or eliminate out-of-pocket costs for eligible patients, typically based on income and insurance status. Independent nonprofit foundations, including the PAN Foundation, the HealthWell Foundation, Good Days, and the Cancer Financial Assistance Coalition, provide grants specifically to cover copays, coinsurance, and related costs for cancer patients on immunotherapy, though funds are limited and availability shifts throughout the year. CancerCare and similar nonprofits also offer direct financial assistance and help navigating the application process. Every major academic cancer center and most community oncology practices have a dedicated financial counselor or navigator whose job is specifically to connect patients with these resources — asking for that referral at the first appointment, rather than waiting for a bill, meaningfully improves the odds of getting help before costs accumulate.

Clinical Trials as a Cost Consideration, Not Just a Research Option

It's also worth noting plainly: patients enrolled in a clinical trial testing a new immunotherapy typically receive the investigational drug itself at no cost to them, funded by the trial sponsor, even though associated care (imaging, standard-of-care components) may still be billed to insurance. For patients facing a difficult cost picture on an approved drug, asking an oncologist about relevant open trials is a legitimate part of the cost conversation, not just an efficacy one.

Bottom Line

Checkpoint inhibitor immunotherapy is expensive enough, on a recurring basis, that cost deserves the same upfront conversation as side effects and expected benefit — not a discussion that happens only after the first statement arrives. Ask your oncology team three specific things before starting treatment: what your plan's prior authorization and coinsurance structure looks like for this specific drug, whether a financial counselor can connect you with manufacturer or nonprofit assistance programs, and whether any open clinical trials could provide the same or a related therapy at no direct cost. None of that changes the clinical case for immunotherapy where it's indicated — it just means going in with eyes open about the bill that follows.